{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T01:48:05Z","timestamp":1726019285989},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,21]]},"DOI":"10.7759\/cureus.26143","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T09:49:17Z","timestamp":1655804957000},"source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab-Induced Acute Skin Reaction: A Case Report and Review of Literature"],"prefix":"10.7759","author":[{"given":"Mathew","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Wazir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarati","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1753465817725486","article-title":"Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence","volume":"11","author":"Rihawi K","year":"2017","unstructured":"Rihawi K, Gelsomino F, Sperandi F, Melotti B, Fiorentino M, Casolari L, Ardizzoni A. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. Ther Adv Respir Dis. 2017, 11:353-73. 10.1177\/1753465817725486","journal-title":"Ther Adv Respir Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins LK","year":"2017","unstructured":"Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017, 41:125-8. 10.1016\/j.currproblcancer.2016.12.001","journal-title":"Curr Probl Cancer"},{"key":"ref3","unstructured":"What is lung cancer? | Types of lung cancer. (2019). Accessed. June 21, 2022: https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/what-is.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart","volume":"10","author":"Travis WD","year":"2015","unstructured":"Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015, 10:1240-2. 10.1097\/JTO.0000000000000663","journal-title":"J Thorac Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.11.019","article-title":"Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy","volume":"52","author":"Osmani L","year":"2018","unstructured":"Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018, 52:103-9. 10.1016\/j.semcancer.2017.11.019","journal-title":"Semin Cancer Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi L","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al.. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018, 378:2078-92. 10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi S","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018, 360:k793. 10.1136\/bmj.k793","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1161_19","article-title":"Case report: bilateral uveitis and papillitis secondary to treatment with pembrolizumab","volume":"67","author":"Navarro-Perea C","year":"2019","unstructured":"Navarro-Perea C, Garcia-Gonzalez J, Perez-Blazquez E. Case report: bilateral uveitis and papillitis secondary to treatment with pembrolizumab. Indian J Ophthalmol. 2019, 67:2075-7. 10.4103\/ijo.IJO_1161_19","journal-title":"Indian J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo M","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, et al.. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015, 151:1206-12. 10.1001\/jamadermatol.2015.1916","journal-title":"JAMA Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi VJ","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S, et al.. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016, 152:1128-36. 10.1001\/jamadermatol.2016.2226","journal-title":"JAMA Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang SJ","year":"2016","unstructured":"Hwang SJ, Carlos G, Wakade D, et al.. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016, 74:455-61.e1. 10.1016\/j.jaad.2015.10.029","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000478081","article-title":"Adverse reactions to biologics: melanoma (ipilimumab, nivolumab, pembrolizumab)","volume":"53","author":"Hwang SJ","year":"2018","unstructured":"Hwang SJ, Fern\u00e1ndez-Pe\u00f1as P. Adverse reactions to biologics: melanoma (ipilimumab, nivolumab, pembrolizumab). Curr Probl Dermatol. 2018, 53:82-92. 10.1159\/000478081","journal-title":"Curr Probl Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al.. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-32. 10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum VR","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA, et al.. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016, 60:12-25. 10.1016\/j.ejca.2016.02.010","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman E","year":"2019","unstructured":"Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019, 80:990-7. 10.1016\/j.jaad.2018.10.062","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000263","article-title":"PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases","volume":"26","author":"Wakade DV","year":"2016","unstructured":"Wakade DV, Carlos G, Hwang SJ, Chou S, Hui R, Fernandez-Pe\u00f1as P. PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Res. 2016, 26:421-4. 10.1097\/CMR.0000000000000263","journal-title":"Melanoma Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21708","article-title":"Pembrolizumab-induced immune-mediated glossitis","volume":"14","author":"Alias A","year":"2022","unstructured":"Alias A, Hall JA, Kulkarni P, Gowan AC. Pembrolizumab-induced immune-mediated glossitis. Cureus. 2022, 14:e21708. 10.7759\/cureus.21708","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21770","article-title":"Bullous pemphigoid associated with pembrolizumab therapy for non-small-cell lung cancer: a case report","volume":"14","author":"Chatterjee T","year":"2022","unstructured":"Chatterjee T, Rashid TF, Syed SB, Roy M. Bullous pemphigoid associated with pembrolizumab therapy for non-small-cell lung cancer: a case report. Cureus. 2022, 14:e21770. 10.7759\/cureus.21770","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos G","year":"2015","unstructured":"Carlos G, Anforth R, Chou S, Clements A, Fernandez-Pe\u00f1as P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015, 25:265-8. 10.1097\/CMR.0000000000000155","journal-title":"Melanoma Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1026","article-title":"Tumoral melanosis associated with pembrolizumab-treated metastatic melanoma","volume":"9","author":"Bari O","year":"2017","unstructured":"Bari O, Cohen PR. Tumoral melanosis associated with pembrolizumab-treated metastatic melanoma. Cureus. 2017, 9:e1026. 10.7759\/cureus.1026","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/77667-pembrolizumab-induced-acute-skin-reaction-a-case-report-and-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:10Z","timestamp":1707507970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/77667-pembrolizumab-induced-acute-skin-reaction-a-case-report-and-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.26143","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,21]]}}}